InsidersTradesSigma
Follow the 차바이오텍 share price and the full management transaction log of the company, a listed equity based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 차바이오텍 has published 6 insider filings. Market capitalisation: €976.2bn. The latest transaction was reported on 3 July 2026 (Other). Among the most active insiders: 차광렬. All data is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
6 of 6 declarations
차바이오텍 is a South Korean biotechnology company focused on developing cell and gene therapies. It is listed on the XKRX market.